Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AdAlta Ltd. ( (AU:1AD) ) has provided an announcement.
AdAlta Ltd. announced the cessation of 6,655,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 29, 2025. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd. operates in the biotechnology industry, focusing on the development of innovative therapeutic products. The company is known for its proprietary i-body technology, which is designed to address challenging disease targets in areas such as fibrosis and cancer.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.